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The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 
2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in 
the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The 
publications and other scientific activities included in the evaluation covered the years 2005–2010. 
The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a 
critical mass with university-level impact, the number of members was set to range from 20 to 120. The 
RCs were required to contain researchers in all stages of their research career, from doctoral students to 
principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary 
evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to 
participate in two communities in certain cases, and 72 of them used this opportunity and participated in 
two RCs. 
This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim 
of the evaluation was not to assess individual performance but a community with shared aims and 
researcher-training activities. The RCs were able to choose among five different categories that 
characterised the status and main aims of their research. The steering group considered the process of 
applying to participate in the evaluation to be important, which lead to the establishment of these 
categories. In addition, providing a service for the RCs to enable them to benchmark their research at the 
global level was a main goal of the evaluation. 
The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms 
and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The 
compilation covered scientific and other publications as well as certain areas of scientific activities. During 
the process, the RCs were asked to check the list of publications and other scientific activities and make 
corrections if needed. These TUHAT compilations are public and available on the evaluation project sites 
of each RC in the TUHAT-RIS. 
In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric 
analyses from the articles included in the Web of Science (WoS). This was done on University and RC 
levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the 
Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 
66 RCs representing the humanities and social sciences. 
The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about 
the organisation of doctoral studies at the University of Helsinki. This and other documents describing the 
University and the Finnish higher education system were provided to the panellists. 
The panel feedback for each RC is unique and presented as an entity. The first collective evaluation 
reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all 
panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to 
complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, 
doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for 
participation in the evaluation. Panellists used the international level as a point of comparison in the 
evaluation. Scoring was not expected to go along with a preset deviation. 
Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 
September to 13 September or from 18 September to 20 September 2011). In these meetings the panels 
also examined the deviations among the scores and finalised the draft reports together. 
The current RC-specific report deals shortly with the background of the evaluation and the terms of 
participation. The main evaluation feedback is provided in the evaluation report, organised according to 











On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your 
participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully 
acknowledged by the University. We wish that you find this panel feedback useful in many ways. The 
bibliometric profiles may open a new view on your publication forums and provide a perspective for 
discussion on your choice of forums. We especially hope that this evaluation report will help you in setting 
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1 Introduction to the Evaluation 
1.1 RC-specific evaluation reports 
The participants in the evaluation of research and doctoral training were Researcher Communities 
(hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the 
evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the 
Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their 
compositions should be considered well-established or new. 
It is essential to emphasise that the evaluation combines both meta-evaluation1 and traditional 
research assessment exercise and its focus is both on the research outcomes and procedures associated 
with research and doctoral training. The approach to the evaluation is enhancement-led where self-
evaluation constituted the main information. The answers to the evaluation questions formed together 
with the information of publications and other scientific activities an entity that was to be reviewed as a 
whole. 
The present evaluation recognizes and justifies the diversity of research practices and publication 
traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with 
low volumes or research distinct from mainstream research. It is challenging to expose the diversity of 
research to fair comparison. To understand the essence of different research practices and to do justice to 
their diversity was one of the main challenges of the present evaluation method. Understanding the 
divergent starting points of the RCs demanded sensitivity from the evaluators. 
1.2 Aims and objectives in the evaluation 
The aims of the evaluation are as follows: 
 to improve the level of research and doctoral training at the University of Helsinki and to raise 
their international profile in accordance with the University’s strategic policies. The improvement 
of doctoral training should be compared to the University’s policy.2 
 to enhance the research conducted at the University by taking into account the diversity, 
originality, multidisciplinary nature, success and field-specificity, 
 to recognize the conditions and prerequisites under which excellent, original and high-impact 
research is carried out, 
 to offer the academic community the opportunity to receive topical and versatile international 
peer feedback, 
 to better recognize the University’s research potential. 
 to exploit the University’s TUHAT research information system to enable transparency of 
publishing activities and in the production of reliable, comparable data. 
1.3 Evaluation method 
The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to 
provide useful information for the enhancement of research and doctoral training of the participating RCs. 
The comparison should take into account each field of science and acknowledge their special character. 
                                                                
1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation 
questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses. 
2
 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.  
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The comparison produced information about the present status and factors that have lead to success. Also 
challenges in the operations and outcomes were recognized. 
The evaluation approach has been designed to recognize better the significance and specific nature of 
researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one 
of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent 
ones. Thus the views of various fields of research can be described and research arising from various 
starting points understood better. The doctoral training is integrated into the evaluation as a natural 
component related to research. Operational processes of doctoral training are being examined in the 
evaluation. 
 
Five stages of the evaluation method were: 
1. Registration – Stage 1 
2. Self-evaluation – Stage 2 
3. TUHAT3 compilations on publications and other scientific activities4 
4. External evaluation 
5. Public reporting 
1.4 Implementation of the external evaluation 
Five Evaluation Panels 
Five evaluation panels consisted of independent, renowned and highly respected experts. The main 
domains of the panels are: 
1. biological, agricultural and veterinary sciences 
2. medicine, biomedicine and health sciences 
3. natural sciences 
4. humanities 
5. social sciences 
The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on 
the suggestions of faculties and independent institutes. Besides leading the work of the panel, an 
additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar 
approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam. 
The panel compositions were nominated by the Rector of the University 27 April 2011. The participating 
RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller 
number of panellists as compared to the previous evaluations was the character of the evaluation as a 
meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated 
answers to the evaluation questions, tables and compilations of publications, other scientific activities, 
bibliometrics and comparable analyses. 
 
The panel meetings were held in Helsinki: 
 On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, 
biomedicine and health sciences and (3) natural sciences.  
 On 18–20 September 2011: (4) humanities and (5) social sciences. 
  
                                                                
3 TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki 
4 Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and 





1.5 Evaluation material 
The main material in the evaluation was the RCs’ self-evaluations that were qualitative in character and 
allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned. 
The present evaluation is exceptional at least in the Finnish context because it is based on both the 
evaluation documentation (self-evaluation questions, publications and other scientific activities) and the 
bibliometric reports. All documents were delivered to the panellists for examination. 
Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences 
when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for 
Science and Technology Studies, University of Leiden, cover only the publications that include WoS 
identification in the TUHAT-RIS. 
Traditional bibliometrics are seldom relevant in humanities and social sciences because the 
international comparable databases do not store every type of high quality research publications, such as 
books and monographs and scientific journals in other languages than English. The Helsinki University 
Library has done analysis to the RCs, if their publications were not well represented in the Web of Science 
databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) 
– it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-
specific bibliometric reports are attached at the end of each report. 
The panels were provided with the evaluation material and all other necessary background information, 
such as the basic information about the University of Helsinki and the Finnish higher education system. 
 
Evaluation material 
1. Registration documents of the RCs for the background information 
2. Self evaluation material – answers to the evaluation questions 
3. Publications and other scientific activities based on the TUHAT RIS: 
3.1. statistics of publications 
3.2. list of publications 
3.3. statistics of other scientific activities 
3.4. list of other scientific activities 
4. Bibliometrics and comparable analyses: 
4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web 
of Science publications (CWTS/University of Leiden) 
4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and 
social sciences 
5. University level survey on doctoral training (August 2011) 





University of Helsinki 
- Basic information about the University of the Helsinki 
- The structure of doctoral training at the University of Helsinki 
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005 
 
The Finnish Universities/Research Institutes 
- Finnish University system 
- Evaluation of the Finnish National Innovation System 
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 
9/09. 
 




1.6 Evaluation questions and material 
The participating RCs answered the following evaluation questions which are presented according to the 
evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For 
giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line 
with the evaluation questions: 
 
1. Focus and quality of the RC’s research 
 Description of 
- the RC’s research focus. 
- the quality of the RC’s research (incl. key research questions and results) 
- the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data 
(provided by University of Leiden and the Helsinki University Library) 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
2. Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
- recruitment and selection of doctoral candidates 
- supervision of doctoral candidates 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
- good practises and quality assurance in doctoral training 
- assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
3. The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with 
public, private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral 
training. 
The additional material: TUHAT compilation of the RC’s other scientific activities. 
A written feedback from the aspects of: societal impact, national and international collaboration, 
innovativeness 
 
  Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 







4. International and national (incl. intersectoral) research collaboration and researcher mobility 
 Description of  
- the RC’s research collaborations and joint doctoral training activities 
- how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and 
researcher mobility, and the actions planned for their development. 
A written feedback from the aspects of: scientific quality, national and international collaboration 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
5. Operational conditions  
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the 
actions planned for their development. 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
6. Leadership and management in the researcher community 
 Description of 
- the execution and processes of leadership in the RC 
- how the management-related responsibilities and roles are distributed in the RC 
- how the leadership- and management-related processes support 
- high quality research 
- collaboration between principal investigators and other researchers in the RC 
the RC’s research focus 
- strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and 
the actions planned for developing the processes 
 
7. External competitive funding of the RC 
 The RCs were asked to provide information of such external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The 
Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other national funding 
organisations, other international funding organisations), and 
2)The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
 
Competitive funding reported in the text is also to be considered when evaluating this point. 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness, future significance 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
8. The RC’s strategic action plan for 2011–2013 
 RC’s description of their future perspectives in relation to research and doctoral training. 
A written feedback from the aspects of: scientific quality, scientific significance, societal Impact, processes 
and good practices related to leadership and management, national and international collaboration, 
innovativeness, future significance 
 Strengths 
 Areas of development 
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 Other remarks 
 Recommendations 
 
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) 
 
The RC’s fitness to the chosen participation category 
A written feedback evaluating the RC’s fitness to the chosen participation category  
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
10. Short description of how the RC members contributed the compilation of the stage 2 material 
Comments on the compilation of evaluation material 
 
11. How the UH’s focus areas are presented in the RC’s research? 
Comments if applicable 
 
12. RC-specific main recommendations based on the previous questions 1–11 
 
13. RC-specific conclusions 
1.7 Evaluation criteria 
The panellists were expected to give evaluative and analytical feedback to each evaluation question 
according to their aspects in order to describe and justify the quality of the submitted material. In 
addition, the evaluation feedback was asked to be pointed out the level of the performance according to 
the following classifications: 
 outstanding  (5) 
 excellent  (4) 
 very good  (3) 
 good   (2) 
 sufficient  (1) 
 
Evaluation according to the criteria was to be made with thorough consideration of the entire 
evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to 
classify their written feedback into one of the provided levels (the levels included respective descriptions, 
‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the 
integers and not rounding up the decimals by the editors. 
 
Description of criteria levels 
Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Outstandingly strong research, also from international perspective. Attracts great international 
interest with a wide impact, including publications in leading journals and/or monographs published 
by leading international publishing houses. The research has world leading qualities. The research 
focus, key research questions scientific significance, societal impact and innovativeness are of 
outstanding quality. 
In cases where the research is of a national character and, in the judgement of the evaluators, should 
remain so, the concepts of ”international attention” or ”international impact” etc. in the grading 





Operations and procedures are of outstanding quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are in 
alignment with the documentation. The ambition to develop the community together is of 
outstanding quality. 
Excellent quality of procedures and results (4) 
Research of excellent quality. Typically published with great impact, also internationally. Without 
doubt, the research has a leading position in its field in Finland. 
Operations and procedures are of excellent quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of excellent quality. 
Very good quality of procedures and results (3) 
The research is of such very good quality that it attracts wide national and international attention. 
Operations and procedures are of very good quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of very good quality. 
Good quality of procedures and results (2) 
Good research attracting mainly national attention but possessing international potential, 
extraordinarily high relevance may motivate good research. 
Operations and procedures are of good quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to large extent in alignment with the documentation. The ambition to develop the 
community together is of good quality. 
Sufficient quality of procedures and results (1) 
In some cases the research is insufficient and reports do not gain wide circulation or do not have 
national or international attention. Research activities should be revised. 
Operations and procedures are of sufficient quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to some extent in alignment with the documentation. The ambition to develop the 
community together is of sufficient quality. 
 
Question 2 – DOCTORAL TRAINING 
Question 3 – SOCIETAL IMPACT 
Question 4 – COLLABORATION 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Procedures are of outstanding quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are in alignment with the 
documentation. The ambition to develop the community together is of outstanding quality. The 
procedures and results are regularly evaluated and the feedback has an effect on the planning. 
Excellent quality of procedures and results (4) 
Procedures are of excellent quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of excellent quality. The 
procedures and outcomes are evaluated and the feedback has an effect on the planning. 
Very good quality of procedures and results (3) 
Procedures are of very good quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
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management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of very good quality. 
Good quality of procedures and results (2) 
Procedures are of good quality, shared occasionally in the community. The practices and quality of 
doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of good quality. 
Sufficient quality of procedures and results (1) 
Procedures are of sufficient quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are occasionally documented and operations and practices are to some extent in 
alignment with the documentation. The ambition to develop the community together is of sufficient 
quality. 
 
Question 9 – CATEGORY 
Participation category – fitness for the category chosen 
The choice and justification for the chosen category below should be reflected in the RC’s responses to the 
evaluation questions 1–8. 
1. The research of the participating community represents the international cutting edge in its field. 
2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
3. The research of the participating community is distinct from mainstream research, and the special 
features of the research tradition in the field must be considered in the evaluation. The research is 
of high quality and has great significance and impact in its field. However, the generally used 
research evaluation methods do not necessarily shed sufficient light on the merits of the 
research.  
4. The research of the participating community represents an innovative opening. A new opening can 
be an innovative combination of research fields, or it can be proven to have a special social, 
national or international demand or other significance. Even if the researcher community in its 
present composition has yet to obtain proof of international success, its members can produce 
convincing evidence of the high level of their previous research. 
5. The research of the participating community has a highly significant societal impact. The 
participating researcher community is able to justify the high social significance of its research. 
The research may relate to national legislation, media visibility or participation in social debate, 
or other activities promoting social development and human welfare. In addition to having 
societal impact, the research must be of a high standard. 
 
An example of outstanding fitness for category choice (5) 5 
The RC’s representation and argumentation for the chosen category were convincing. The RC recognized 
its real capacity and apparent outcomes in a wider context to the research communities. The specific 
character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the 
category. 
 
 Outstanding  (5) 
 Excellent  (4) 
 Very good  (3) 
 Good   (2) 
 Sufficient  (1) 
The above-mentioned definition of outstanding was only an example in order to assist the panellists in 
the positioning of the classification. There was no exact definition for the category fitness. 
                                                                





1.8 Timetable of the evaluation 
The main timetable of the evaluation: 
1. Registration   November 2010 
2. Submission of self-evaluation materials  January–February 2011 
3. External peer review    May–September 2011 
4. Published reports    March–April 2012 
- University level public report 
- RC specific reports 
 
The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary 
results were available for the planning of the following strategy period in late autumn 2011. The evaluation 
reports will be published in March/April 2012. More detailed time schedule is published in the University 
report. 
1.9 Evaluation feedback – consensus of the entire panel 
The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the 
draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists 
on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft 
reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued 
working and finalised the reports before the end of November 2011. The final RC-specific reports are the 
consensus of the entire panel. 
The evaluation reports were written by the panels independently. During the editing process, the 
evaluation office requested some clarifications from the panels when necessary. The tone and style in the 
reports were not harmonized in the editing process. All the reports follow the original texts written by the 
panels as far as it was possible. 
The original evaluation material of the RCs, provided for the panellists is attached at the end of the 
report. It is essential to notice that the exported lists of publications and other scientific activities depend 









2 Evaluation feedback 
2.1 Focus and quality of the RC’s research 
 Description of 
 the RC’s research focus 
 the quality of the RC’s research (incl. key research questions and results) 
 the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness 
 
This RC is an apparently tight and mutually beneficial collaborative network of two world-class established 
PIs and a third somewhat more junior PI who also has a very good track record. Together these PIs and 
their research groups master the multidisciplinary expertise necessary for top notch research in the rapidly 
developing field of cancer genomics. 
The scientific excellence of this RC is obvious. The group has been shortlisted for an Academy of 
Finland Centre of Excellence (CoE), two of the PIs are Academy of Finland professors and have a European 
Reseach Council (ERC) advanced grant and their individual track records are outstanding. They also have 
shared publications. In addition to the obvious excellence of the individual PIs in the consortium, their 
collaboration brings the added benefit of combining expertise in different areas. Dr. Hautaniemi’s team is 
expert in computational systems biology. Professor Aaltonen’s group is expert in tumor genomics and 
Professor Taipale has set up world-class methodology for high-throughput screening and bioinformatics 
to allow a systems biology approach for the investigation of cancer cell biology. 
Taken together, this is clearly an RC which is second to a few in Finland and brings together top PIs 
working with outstanding resources with complementary skills and expertise. The practical impact of the 
fact that one of the PIs is mainly working in Stockholm is not clearly discussed and the description that 
"the physical location next to each other provides excellent means to easily organize efforts" (5 
Operational condition) considered by the panel as somewhat conflicting. 
Numeric evaluation: 5 (Outstanding) 
2.2 Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
 recruitment and selection of doctoral candidates 
 supervision of doctoral candidates 
 collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
 good practises and quality assurance in doctoral training 
 assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
 Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
ASPECTS: Processes and good practices related to leadership and management 
 
The RC has a good track record in training PhDs. Thus far 24 PhD theses have been supervised, ten of 
these have been approved with distinction and several have won prizes. The PIs are also involved in the 




The RC finds it easy to recruit top students due to their excellent publication record and evidence for 
good practical hands-on supervision. Each student is supervised by a PI and a junior researcher, progress 
of the thesis is monitored in supervisory committees and regular meetings. A clear system has been set up 
where the demands for the student are gradually increased every year during their studies with the aim to 
support independence and maturity as scientists. The panel finds the doctoral training to be of very high 
quality. 
For post-doctoral fellows, it is recognized that the aim of their training is to learn skills needed to 
become an independent PI. This is important. 
One of the challenges of the RC is that due to the multidisciplinary nature of the research, it may be 
difficult to recruit students with expertise in biology, genomics and computational sciences. The aim of the 
RC is to train scientists in a cross-disciplinary manner. Based on the material submitted, the RC feels that 
the UH is not supportive enough of such training and this should be improved. 
Numeric evaluation: 5 (Outstanding) 
2.3 The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training. 
 Additional material: TUHAT compilation of the RC’s other scientific activities. 
ASPECTS: Societal impact, national and international collaboration, innovativeness 
 
Outstanding research is always closely linked with high societal impact, good collaborations both 
nationally and internationally as well as a generation of innovations. This RC has clearly contributed in all 
of these areas. 
The RC has a good track record in training PhDs. Thus far 24 PhD theses have been supervised. In 
addition, many post-docs have received training in these groups. The impact of training these top experts 
should not be underestimated. The PIs in this RC have also been active in policy making and have been 
involved in many positions responsible for development and management of the Finnish bioscience 
research and legislation. 
The group has actively communicated their scientific discoveries to the public. 
Most importantly, their science has generated innovations and breakthroughs with clinical and 
commercial impact. 
The RC plans to continue their active role in communicating science to the general public and in 
engaging in discussion with experts in different forums. 
Numeric evaluation: 5 (Outstanding) 
2.4 International and national (incl. intersectoral) research 
collaboration and researcher mobility 
 Description of  
 the RC’s research collaborations and joint doctoral training activities 
 how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and researcher 
mobility, and the actions planned for their development. 
ASPECTS: Scientific quality, national and international collaboration 
 
The members of this RC have strong national and international collaborations. This is evident both from 





The top-class research of these groups has facilitated their ability to establish necessary international 
collaborations. At present they are involved in two of EU’s Seventh Framework Programme (FP7) 
consortia and have an impressive list of international collaborators. 
The strong existing international links and the commitment to promote student mobility guarantee that 
students and post-docs working in the groups will be offered with possibilities for research exchange and 
international meetings. It is important that this kind of international training and gaining of experience is 
supported by the RC and students are actively encouraged to participate in such activities. 
Numeric evaluation: 5 (Outstanding) 
2.5 Operational conditions 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the actions 
planned for their development. 
ASPECTS: Processes and good practices related to leadership and management 
 
All of the three groups of this RC are very well funded. They work in environments with the best 
infrastructure and resources. In addition to the standard research requirements, the ability to exploit the 
unique Finnish resource, the Finnish Cancer Registry, is key to their research. They also have good national 
connections to clinical pathology departments. 
At present, all the resources necessary for their continued success seem in place. However, it is 
important to emphasize that continued investment in research infrastructure in the UH and Finland is 
absolutely critical. The fact that one of the groups is predominantly working in Stockholm might hamper 
the close collaboration described by the RC in their documents. 
2.6 Leadership and management in the researcher community 
 Description of  
 the execution and processes of leadership in the RC 
 how the management-related responsibilities and roles are distributed in the RC 
 how the leadership- and management-related processes support 
 high quality research 
 collaboration between principal investigators and other researchers in the RC 
 the RC’s research focus 
 strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and the 
actions planned for developing the processes 
ASPECTS: Processes and good practices related to leadership and management 
 
Rather than presenting a clear hierarchical management structure, the RC relies on PI driven management 
of the individual groups. In addition, they rely on the science and the efforts needed for scientific 
discoveries in guiding the necessary actions. This seems like the best possible management structure since 
science, not predetermined structures or goals, should be the primary director of research efforts also 
elsewhere. Thus the RC is composed of three independent groups working together. 
Within the groups the supervision has been organized by sharing the responsibility between the PIs 
and other senior scientists in the group. Know-how is actively shared between the groups. In their material 
the RC emphasizes how close physical location of the groups is key to collaboration. This seems a bit odd 
as one of the groups is predominantly located in Sweden. 
The current organization is clearly functioning well and no major changes are needed. 
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2.7 External competitive funding of the RC 
• The RCs were asked to provide information of such external competitive funding, where: 
• the funding decisions have been made during 1.1.2005–31.12.2010, and  
• the administrator of the funding is/has been the University of Helsinki 
• On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, 
TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other 
national funding organisations, other international funding organizations), and 
2) The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
Competitive funding reported in the text is also to be considered when evaluating this point. 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance 
 
The funding of the RC is exceptional in volume and in versatility. Significant funding has been secured 
from many national as well as international sources. The RC has been very successful in winning highly 
competitive funding, such as ERC advanced grants. 
2.8 The RC’s strategic action plan for 2011–2013 
• RC’s description of their future perspectives in relation to research and doctoral training. 
ASPECTS: Scientific quality, scientific significance, societal Impact, processes and good practices related to 
leadership and management, national and international collaboration, innovativeness, future significance 
 
The RC has been shortlisted for an Academy of Finland CoE position for the next five years. These plans 
are likely to shape the future collaboration. The groups plan to collaborate in research falling under three 
main goals: 1) Identification of cancer predisposition genes, 2) Characterization of common cancer 
susceptibility variant and 3) Characterization of mutatomes. 
These are all important goals with significant clinical and societal impact. It is likely that world-class 
science will be achieved also in the future related to the goals and others. 
The training provided by the RC has been excellent in the past and the plans are to continue providing 
excellent PhD student training. Also international student training will be an emphasis in the future as well. 
International collaborations will be continued for example in the form of EU consortia. 
2.9 Evaluation of the category of the RC in the context of entity of 
the evaluation material (1-8) 
The RC’s fitness to the chosen participation category. 
Category 1. The research of the participating community represents the international cutting edge in its field. 
 
The category chosen is particularly suitable for this RC. It is clear that their research and doctoral training 
represent the international cutting edge in its field. 
This is evident based on all the evaluation criteria. The scientific track-record is outstanding. The 
secured funding is exceptionally high, the research environment is the best in Finland and the training of 
young researchers is of a high standard. 





2.10 Short description of how the RC members contributed the 
compilation of the stage 2 material 
— 
2.11 How the UH’s focus areas are presented in the RC’s research 
Focus area 2: The basic structure of life 
2.12 RC-specific main recommendations 
The RC is clearly world class and the collaboration of the three groups with distinct expertise is clearly 
mutually beneficial. The groups have clearly found their own niche which is combining clinical and 
epidemiological data with modern genomics, systems biology approaches and computational science. The 
recommendation is: “Keep up the good work!” 
2.13 RC-specific conclusions 
This RC is clearly world-class and an example to others in setting high standards and achieving them. All 
the aspects to be evaluated: Science, collaborations, training of students and post-docs, societal impact 
and fitting with the UH strategy are all at their highest levels. No major changes are suggested. 
2.14 Preliminary findings in the Panel-specific feedback 
Everything is excellent. 
2.15 Preliminary findings in the University-level evaluation 
Again, everything is as good as it gets. The groups have found their own research tracks where they 
clearly excel and the collaborations between the groups seem to be mutually beneficial and clearly bring 
added value.  
The groups have a great track record in doctoral training with over 20 supervised PhD theses and many 
of them approved with honors. In addition, many of the post-docs trained by these RCs have found 
suitable work after leaving the laboratories, warranting commendation. 
The world-class medical research carried out by the groups is likely to have an important societal 
impact in facilitating the development of future cures. In addition, the groups have been actively 
communicating their findings to the general public. The PIs have also been actively involved in policy 
making. 
The groups are predominantly managed by the shared commitment to pursue top science. Supervision 
in the individual groups appears to be relatively well organized and no suggestions for improvement are 
suggested by the panel. 
The RC has been able to attract high levels of internationally competitive funding like ERC advanced 
grants. Their external funding is thus in very good shape and could hardly be better. 
The plans of the RC for future collaboration and research are convincing and exciting, and the panel is 
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NAME OF THE RESEARCHER COMMUNITY:  
Cancer Systems Biology RC (CSB) 
 
LEADER OF THE RESEARCHER COMMUNITY:  
Academy Professor Lauri Aaltonen, Research Programs Unit, Faculty of medicine 
 
 
RC-SPECIFIC MATERIAL FOR THE PEER REVIEW: 
 Material submitted by the RC at stages 1 and 2 of the evaluation 
- STAGE 1 material: RC’s registration form (incl. list of RC participants in an excel table) 
- STAGE 2 material: RC’s answers to evaluation questions 
 TUHAT compilations of the RC members’ publications 1.1.2005-31.12.2010 
 TUHAT compilations of the RC members’ other scientific activities 1.1.2005-31.12.2010 
 Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010 
(analysis carried out by CWTS, Leiden University) 
NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing 
humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library 






INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 




Name: Aaltonen, Lauri 
E-mail:  
Phone: 09-19125595 
Affiliation: Academy Professor 
Street address: Haartmaninkatu 8 
 
 
Name of the participating RC (max. 30 characters): Cancer Systems Biology RC 
Acronym for the participating RC (max. 10 characters): CSB 
Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training 
activities) on which the RC was formed (MAX. 2200 characters with spaces): The practical motivation for 
forming the research community (RC) originates from the vast methodological progress in genomics. The 
availability of multiple high-throughput platforms has resulted in massive accumulation of 
multidimensional and heterogeneous molecular data , which needs to be interpreted with approaches 
requiring wide range of expertise from genetics to biochemisty and computer science. Thus the Aaltonen / 
Tumor Genomics Group has formed a strong partnership with the Taipale / Medical Systems Biology Group 
and Hautaniemi / Computational Systems Biology Group to achieve a multidisclipinary community that 
focuses on gaining comprehensive understanding of cancer progression and identifying targets for effective 
anti-cancer therapeutics.  
The three groups have strong history as working within the same unit within the University of Helsinki; 
Genome-Scale Biology research program / Research program Unit of the UH Faculty of Medicine. The three 
groups also have a common future, not only as part of the research program but the three PIs together 
with two others form the proposed Academy of Finland’s Center of Excellence in Cancer Genetics; this 
proposal has progressed to the shortlist of 36 candidate CoEs with maximum scores. 
Like any scientifically strong collaboration, the RC has significantly supported the doctoral training in the 
three participating groups. While all three PIs have had a significant impact for UH doctoral training e.g. by 
serving in Graduate School Boards -  Biomedical Graduate School, Helsinki Graduate School in 
Biotechnology and Molecular Biology, and Finnish National Graduate School in Computational Biology - the 
impact of the RC to internal doctoral training is also an important focus of this review. Here the simple and 
strong scientific synergy has led to multidisclipinary joint efforts and joint publications, forming a solid basis 
to prize-winning PhD thesis works originating from this RC. 
 
 
Main scientific field of the RC’s research: medicine, biomedicine and healt sciences 
RC's scientific subfield 1: Genetics and Heredity 
1 RESPONSIBLE PERSON 
2 DESCRIPTION OF THE PARTICIPATING RESEARCHER COMMUNITY (RC) 
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RC's scientific subfield 2: Medical Informatics 
RC's scientific subfield 3: Oncology 
RC's scientific subfield 4: --Select-- 
Other, if not in the list:  
 
 
Participation category: 1. Research of the participating community represents the international cutting 
edge in its field 
Justification for the selected participation category (MAX. 2200 characters with spaces):  Simply a glance 
at the list of publications should be sufficient to conclude that the “cutting edge research” category best fits 
our RC. The many key discoveries made within this RC including identification of multiple cancer 
predisposition genes and innovative use of high throughput technologies and computational methods leave 
little room for other choices. 
2 of 3 PIs are Academy professors – the highest rank in the Finnish research hierarchy - and have been 
selected for an ERC advanced grant which is probably the most competed funding instrument directed to 
single PIs. One could continue the justification with many other merits but clearly of the five available 
categories only number one, “cutting edge research”, would be an appropriate choice and any other choice 
would appear odd. 
 
 
Public description of the RC's research and doctoral training (MAX. 2200 characters with spaces): Cancer 
is a disease involving two unique genomes – germline, and that of the respective tumor. The rapid 
advances in genomic technologies are now enabling whole genome analysis of individuals and cancers. This 
will finally allow thorough dissection of germline and somatic genetic variation contributing to neoplasia. 
The RC has made seminal discoveries in this field on the highest international level, thriving on the 
powerful synergistic combination of advancing technologies, unique national materials and infrastructure, 
and sophisticated data analyses. 
This multidisciplinary RC integrates clinical characteristics and molecular epidemiology of cancer 
predisposition into genomics and medical and computational systems biology. Within the RC the 
participating groups have invested heavily to ensure that the young PhD students get the best possible 
supervision. Often two supervisors have been appointed for a thesis project, the PI and one of the other 
senior team members. This has ensured that also day-to-day hands-on supervision is available to all 
students. The RC groups have also been extremely supportive towards courses, visits, and similar activities 
which enable the students to gain a broader understanding of the field, and science in general. 
The three PIs in the RC are from different backgrounds (medicine, biology, engineering). This, together with 
the interdisciplinary nature of the consortium results in formation of supportive, creative and inspirational 
research environment that enables both top-level research, and training of a new generation of scientists 
who will have the necessary skills to excel in their future careers and contribute to the ongoing 
transformation of biomedicine from largely qualitative and descriptive approaches towards more exact, 
4 RC'S PARTICIPATION CATEGORY 
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quantitative and predictive science. The Aaltonen laboratory received the UH's Occupational Safety and 
Health Award 2005 as a formal acknowledgement of excellent working atmosphere, and this reflects the 
spirit of the whole RC. 
Significance of the RC's research and doctoral training for the University of Helsinki (MAX. 2200 
characters with spaces): The core contribution of the RC’s research – for UH and others - is its impact into 
scientific progress. This is best documented by the high quality publications the PIs have coauthored during 
the evaluation period; please see the lists of publications. Additional prestige for the University has been 
provided through the 5EU fwp grants coordinated by the PIs during this time window, many science prizes, 
and in particular the two ERC advanced grants won by the RC PIs.  
In doctoral training the RC PIs have supervised 24 PhD thesis projects. The results have been excellent; e.g. 
UH Medical Faculty thesis prize 1999, U of Oulu Medical Faculty thesis prize 2007, the UH thesis prize 2004 
and 2008. Several thesis works have been approved with distinction, by far exceeding the average <10% 
receiving this mark. The CoE PIs are represented in Boards of all the relevant Graduate Schools; Helsinki 
Biomedical Graduate School, Helsinki Graduate School in Biotechnology and Molecular Biology, and Finnish 
National Graduate School in Computational Biology. Thus the commitment of the RC to the curricula of the 
Graduate Schools is firm and the link between the RC and the Graduate Schools couldn’t be tighter. 
The groups in this RC are active in technology transfer, and, for instance, computational system biology 
group has hosted three PhD students from Italy, Norway and Finland in 2010 alone and has sent students to 
Netherlands and MIT for longer research visits. The goal for these students was to learn to use and apply 
herein developed computational tools to their data. Bilateral research exchange is significant to Univ. of 
Helsinki in pragmatic view of getting opportunities for our students to collaborate with cutting-edge groups 
as well as branding view of demonstrating that research conducted in the UH attracts the scientific 
community. 




Justified estimate of the quality of the RC's research and doctoral training at national and international 
level during 2005-2010 (MAX. 2200 characters with spaces): The RC represents scientific stature in 
research, which is second to few in Finland. This is exemplified by some of our first/last author papers 
2005-10: Hallikas O, et al. Genome-wide prediction of mammalian enhancers based on high-throughput 
analysis of transcription factor binding affinity. Cell 124, 47-59, 2006. Vierimaa O, et al. Pituitary adenoma 
predisposition caused by germline mutations in the AIP gene. Science 312, 1228-1230, 2006. Björklund M, 
et al. Identification of pathways regulating cell size and cell cycle progression by RNAi. Nature 439, 1009-
1013, 2006. Varjosalo M, et al. Application of active and kinase-deficient kinome collection for identification 
of kinases regulating Hedgehog signaling. Cell 133, 537-548, 2008. Wu J, et al. Integrated network analysis 
platform for protein-protein interactions. Nature Methods 6, 75-7, 2009 Tuupanen S, et al. The common 
colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt 
signaling. Nature Genetics 41, 885-890, 2009. 
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Our track record in researcher training is excellent, with 24 thesis works supervised, 10 of which have been 
approved by distinction. The 2005-2010 results have been outstanding; 17 completed thesis work, 8 of 
which have been approved with distinction, and e.g. U of Oulu Medical Faculty thesis prize 2007, the best 
bioinformatics/systems biology PhD thesis of the year 2008 in Finland by the Finnish Bioinformatics Society, 
and the UH thesis prize 2008.  
The RC has been active as organiser of courses and other forms of training, such as graduate school 
activities: Aaltonen being in the Board of the Helsinki Biomedical Graduate School and serving as a tutor for 
the MD PhD program, U of Helsinki; Taipale being in the boards of Graduate Schools in Biotechnology and 
Molecular Biology and Computational biology. Hautaniemi is active in teaching computational methods to 
new generations of bioinformaticians as well as to biologists, and has organized two seminar courses and 
two lecture courses on using computational methods in biological data in the past three years. 
Comments on how the RC's scientific productivity and doctoral training should be evaluated (MAX. 2200 
characters with spaces): 1. Quality of publications 
2. Prizes won by PIs 
3. Success in deriving competed funding 
4. Success in competing for positions 
5. Number and quality of PhD thesis 
6. Prizes and distinctions won by the PhD students 
RC's publication strategy is to publish the work in high quality journals as with as little delay as possible. 
Data is also shared before publication in some of the consortia, in particular COGENT (aim to take genome-
wide association studies forward as a multicenter international consortium) and SYNERGY (Systems 
approach to gene regulation biology through nuclear receptors). Communicating key results to the public 
after successful scientific peer-review has also been important. This, however, does not mean that the 
materials, methods and results would not be discussed before the publication. The students in this RC are 
encouraged to actively discuss and present on-going work to fellow students in the two other labs. The fact 
that Aaltonen, Hautaniemi and Taipale labs are physically next to each other facilitates significantly 
collaboration between the groups. 
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: Cancer Systems Biology RC
RC-LEADER L. Aaltonen
Category 1




Title of research and 
teaching personnel Affiliation 
1 Aaltonen Lauri x professor Faculty of medicine/Research Programs Unit
2 Aavikko Mervi doctoral candidate Faculty of medicine/Research Programs Unit
3 Alhopuro Pia postdoctoral researcher Faculty of medicine/Research Programs Unit
4 Gylfe Alexandra doctoral candidate Faculty of medicine/Research Programs Unit
5 Heliövaara Elina doctoral candidate Faculty of medicine/Research Programs Unit
6 Kaasinen Eevi doctoral candidate Faculty of medicine/Research Programs Unit
7 Karhu Auli senior researcher Faculty of medicine/Research Programs Unit
8 Kondelin (os. Sirkiä) Johanna doctoral candidate Faculty of medicine/Research Programs Unit
9 Launonen Virpi x senior researcher Faculty of medicine/Research Programs Unit
10 Lehtonen Heli postdoctoral researcher Faculty of medicine/Research Programs Unit
11 Mehine Miika doctoral candidate Faculty of medicine/Research Programs Unit
12 Niittymäki Iina doctoral candidate Faculty of medicine/Research Programs Unit
13 Saarinen Silva doctoral candidate Faculty of medicine/Research Programs Unit
14 Tuupanen Sari postdoctoral researcher Faculty of medicine/Research Programs Unit
15 Vahteristo Pia senior researcher Faculty of medicine/Research Programs Unit
16 Hautaniemi Sampsa x research director Faculty of Medicine/Research Programs Unit
17 Chen Ping doctoral candidate Faculty of Medicine/Research Programs Unit
18 Karinen Sirkku doctoral candidate Faculty of Medicine/Research Programs Unit
19 Laakso Marko doctoral candidate Faculty of Medicine/Research Programs Unit
20 Lahesmaa-Korpinen Anna-Maria doctoral candidate Faculty of Medicine/Research Programs Unit
21 Louhimo Riku doctoral candidate Faculty of Medicine/Research Programs Unit
22 Núñez Fontarnau Javier postdoctoral researcher Faculty of medicine/Research Programs Unit
23 Ovaska Kristian doctoral candidate Faculty of Medicine/Research Programs Unit
24 Rantanen Ville doctoral candidate Faculty of Medicine/Research Programs Unit
25 Rogojin Vladimir postdoctoral researcher Faculty of Medicine/Research Programs Unit
26 Wu Jianmin postdoctoral researcher Faculty of Medicine/Research Programs Unit
27 Taipale Jussi x professor Faculty of Medicine/Research Prgrams Unit
28 Bonke Albertus postdoctoral researcher Faculty of Medicine/Research Prgrams Unit
29 Hallikas Outi postdoctoral researcher Faculty of Medicine/Research Prgrams Unit
30 Jolma Arttu doctoral candidate Faculty of Medicine/Research Prgrams Unit
31 Li Song-Ping postdoctoral researcher Faculty of Medicine/Research Prgrams Unit
32 Sokolova Maria postdoctoral researcher Faculty of Medicine/Research Prgrams Unit
33 Turunen Mikko doctoral candidate Faculty of Medicine/Research Prgrams Unit
34 Vähärautio (os. Saramäki) Anna
senior researcher (academy 
research fellow)
Faculty of Medicine/Research Prgrams Unit
35 Wei Gonghong postdoctoral researcher Faculty of Medicine/Research Prgrams Unit
36 Yan Jian doctoral candidate Faculty of Medicine/Research Prgrams Unit
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Name of the RC’s responsible person: Aaltonen, Lauri 
E-mail of the RC’s responsible person:   
Name and acronym of the participating RC: Cancer Systems Biology, CSB 
The RC’s research represents the following key focus area of UH: 2. Elämän perusrakenne – The basic 
structure of life 
Comments for selecting/not selecting the key focus area: This RC represents a coalition of three active, 
world-class research groups, whose main focus is to characterize genetic mechanisms of human cancer 
predisposition and progression using a holistic, systems biology approach. The published results of the RC 
members have revealed a number of important and novel discoveries on genetics and systems biology, 
which belong to the key focus area of “2. The basic structure of life” by the University of Helsinki strategy. 
Furthermore, Jussi Taipale and Lauri Aaltonen are members of one of the Centers of Excellence listed in the 
strategy plan at this focus area, and our new Center of Excellence (CoE) proposal ”Cancer Genetics”  (now 
shortlisted for final decision) which involves all the three RC groups (Aaltonen, Taipale & Hautaniemi) 
clearly falls under this focus area as well. 
 
 
 Description of the RC’s research focus, the quality of the RC’s research (incl. key research 
questions and results) and the scientific significance of the RC’s research for the research 
field(s).  
The RC`s research focus 
The focus of the Cancer Systems Biology (CSB) RC is to examine cancer patient samples - carefully 
selected from the Finnish population - using state-of-the-art technologies to comprehensively 
characterize the genetic profiles and their connections to cancer using holistic systems biology 
approach. Cancer is a disease involving two unique genomes; germline, and that of the respective 
tumor. These genomes can now be read using high throughput analysis technologies. This allows a 
thorough dissection of germline and somatic genetic variation contributing to neoplasia. Accordingly, 
systematic large-scale efforts to characterize tumor genomes are underway under the umbrella of the 
International Cancer Genome Consortium (ICGC) and elsewhere. The members of RC are contributors in 
these efforts. Key discoveries are anticipated in the following fields of research relevant for CSB 
Research Community (for more details see section 8): 
i) Identification of high/moderate-penetrance cancer predisposition conditions, and the respective 
susceptibility genes. 
ii) Characterization of common cancer susceptibility variants. In particular, little is known about the 
biology underlying these variants – starting from identification of the causative variants from the 
associated genomic regions. 
iii) Characterization of mutatomes of all clinically relevant tumor types; in CSB colorectal cancer and 
uterine leiomyomas are in focus.  
 
The quality and the scientific significance of the RC's research 
Genetics of cancer is a key field of the medical research, in which Finland and the members of the CSB 
have excellent traditions in advancing the field at the highest international level.  CSB thrives on the 
BACKGROUND INFORMATION 
1 FOCUS AND QUALITY OF RC'S RESEARCH (MAX. 8800 CHARACTERS WITH SPACES) 
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powerful synergistic combination of advancing technologies, unique national materials and 
infrastructure, and sophisticated data analyses, to take human cancer genetics research to a new level, 
and finally to translate the molecular findings into clinical benefits, such as novel approaches in risk 
prediction, prevention, diagnosis, and treatment. 
CSB represents scientific stature in health research, which is second to few or none in Finland. The three 
groups in CSB have made seminal discoveries in the field of cancer research on the highest international 
level. This is best documented by the high quality publications he PIs have published during the 
evaluation period. Additional prestige for the University has been provided through the 4 EU grants 
coordinated by the PIs during this time window, many science prizes, and in particular the two ERC 
Advanced Grants won by the RC PIs (Taipale 2008 Aaltonen 2010). 
Some of our last author papers 2005-2010:  
Hallikas O, et al. Genome-wide prediction of mammalian enhancers based on high-throughput analysis 
of transcription factor binding affinity. Cell 124, 47-59, 2006. 
Vierimaa O, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. 
Science 312, 1228-1230, 2006. 
Björklund M, et al. Identification of pathways regulating cell size and cell cycle progression by RNAi. 
Nature 439, 1009-1013, 2006. 
Varjosalo M, et al. Application of active and kinase-deficient kinome collection for identification of 
kinases regulating Hedgehog signaling. Cell 133, 537-548, 2008. 
Wu J, et al. Integrated network analysis platform for protein-protein interactions. Nature Methods 6, 75-
77, 2009. 
Tuupanen S, et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 
confers potential to enhanced Wnt signaling. Nature Genetics 41, 885-890, 2009. 
 
A brief account on the Groups: 
Tumor genomics group / Aaltonen (CSB coordinator) Aaltonen, is a second term Academy Professor; 
received this position in 2002 at the age of 39. The main current administrative positions; Director, 
Genome-Scale Biology research program, University of Helsinki & Director, Biocentrum Helsinki. 
Publications have been cited >17.500 times. Of other merits e.g. the EMBO membership in 2000, Anders 
Jahre Prize for Young Researchers 2000, being a nominee for the Descartes prize 2005 with Prof. 
Tomlinson and ERC Adv Grant 2010, are useful indicators. The core field of research is tumor genomics, 
in particular molecular basis of cancer susceptibility. The track record in cancer genetics speaks for itself. 
Medical systems biology group / Taipale  Taipale holds a joint appointment as an Academy of Finland 
Professor (40%) and Professor of Medical Systems Biology at the Karolinska Institutet, Sweden (60%). 
Focus of the Taipale group is on systems biology of growth control and cancer. Prof. Taipale has 
published 40 articles of which nine are in the most prestigious scientific journals (Nature, Science, Cell). 
He has won numerous awards and grants (e.g. Anders Jahre Prize for Young Researchers, EMBO Young 
Investigator, ERC Advanced Grant), and is internationally recognized as a leader in the field of genomics 
and systems biology. The Taipale group brings to the RC expertise on high-throughput screening using 
cDNA and RNA interference, and computational and experimental methods to identify causative 
regulatory mutations in non-protein coding DNA and to analyze genetic networks. In addition, Taipale 
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Computational systems biology group / Hautaniemi Hautaniemi is an Academy Research Fellow and 
started his group at spring 2006 after extremely successful post-doc period in the Douglas A. 
Lauffenburger laboratory at MIT. With 46 publications cited >1300 times and h-index of 18 Hautaniemi 
is a recognized systems biologist who has served in a number of conference program committees, such 
as ISMB/ECCB 2009 (the largest systems biology annual meeting), reviewed systems biology grant 
applications in EU and USA, such as NIH R01 supplement grants, and coordinates national and 
international bioinformatics/systems biology consortiums. The main objective of the Hautaniemi group 
is to develop and apply novel computational methodologies to characterize and control cell decision 
processes in cancer. 
 Ways to strengthen the focus and improve the quality of the RC’s research. 
Cancer is a complex group of diseases and to characterize origin of tumors using high-quality data 
requires a truly cross-disciplinary team of researchers. This RC brings together expertise in medicine 
(LA), biochemistry (JT) and engineering (SH), which are the key disciplines enabling systematic and 
innovative cancer research. A major strength of this RC is that the groups are physically close in the 
excellent research infrastructure in Biomedicum. CSB is a prime example of multidisciplinary research 
team that has a clearly defined and innovative vision.  
To upgrade our efforts we have now submitted an application for an Academy of Finland’s Center of 
Excellence status, and further broadened our approach by including computer scientists to facilitate 
sequence analysis (Professor Veli Mäkinen), as well as epidemiologists to facilitate patient selection (the 
unique Finnish Cancer Registry, Professor Timo Hakulinen as Director). This application has been 
shortlisted for final funding decisions (36 out of 135 proposals were shortlisted after international 
review), expected in June 2011. 
 
 
  How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and 
selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, 
departments/institutes, and potential graduate schools/doctoral programmes, good practises and 
quality assurance in doctoral training, and assuring good career perspectives for the doctoral 
candidates/fresh doctorates.  
Recruitment and selection of doctoral candidates. 
Our basic principle of doctoral training we provide is that excellence in research and hands-on 
supervision attracts the best students from Finland and abroad, and results in very competitive PhDs 
who can continue conducting high impact research in academia or industry. We are open for 
applications year round and the background of the students vary from pure mathematics to medicine 
and the procedure of handling the applications varies. For students already enrolled to the MD PhD 
program of the medical faculty the procedure proceeds as follows. The MD PhD Program is a joint 
program between the Biomedical Graduate School, Faculty of Medicine and other Meilahti Campus 
Graduate Schools. The students are selected amongst the first year MD students, and they start their 
graduate education by doing rotations in research groups during their first two summers, including one 
clinical rotation. The CSB almost always can provide a rotation slot for an interested student. Following 
this the students choose their research group and thesis project and continue doing their research side 
by side with their medical studies for approximately three years; however, the prerequisite for this step 
is that the student’s performance during the CSB rotation period has met our standards, in view of 
scientific potential as well as ability for team work. Having finished their MD degree, the students 
continue with full-time research with their thesis project until the defense of their thesis. The selection 
of students from other fields, such as biology, mathematics and computer science, is performed based 
2 PRACTISES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES) 
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on transcripts, interview and recommendations of the applicants. In the interview there is always at 
least one post-doc and PhD student included. The number of applications we receive per year is around 
300. Of these, on average 30 are invited to an interview and around 20 are hired. 
 
Supervision of doctoral candidates. 
A doctoral student is exposed to the four essential fields of research (research, grant application writing, 
peer-review, teaching) in a controlled and gradual manner. During the first two years, a PhD student is 
expected to accomplish studies and the research projects are clearly defined. Projects are supervised by 
late-stage PhD students and post-docs in addition to PI. After successfully contributing two projects, the 
independence level of the student is increased with delineating the objective of the research and 
expecting him/her to suggest a plan how to achieve this goal. The plan is discussed with PI and post-docs 
and after approval, the student starts executing the plan. Simultaneously, student is exposed to peer-
review journal paper the PI is asked to review. While PI writes the review, the student writes his/her 
own critique and the points of the paper are discussed together; confidentiality requirements of peer-
review are strictly adhered to. This way our students get a better understanding of the scientific peer-
review procedure, and can plan their own papers accordingly. The students are also encouraged to 
apply for personal grants, as well as contribute small portions of large EU grant proposals/reports the 
PIs are writing. Exposure to grant writing and reporting helps students to express their results and plans 
in a clear fashion, which facilitates dissemination of the results to public and newspapers/magazines. In 
addition, students are expected to teach at least in one graduate school course, or a course or lecture at 
the undergraduate level. This way we expect to train senior researchers who have both a strong 
publication record as well as solid skills in teaching and grant writing, to be able to successfully compete 
for tenure track positions in the UH and elsewhere; currently the most difficult bottleneck in research 
careers.  
Postdoctoral training During post-doctoral fellowship one should learn the skills required to become a 
professional scientist, with a clear, independent research interest and direction. The only way of 
learning to become independent is to have responsibility and say in one’s own projects. It is also critical 
to learn how to direct students, and teach at the university level. These skills are also required for 
receiving a docentship, a key requirement for career advancement, and an important aim of a successful 
post-doc period. Therefore, after 1-1.5 years, when the post-doctoral scientist is familiar with the 
research topic, and has developed scientific self-confidence, s/he will also take the responsibility of 
directing one or two graduate students. 
 
Collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes. 
Given the multidisciplinary nature of our RC, we contribute to several graduate schools and doctoral 
programs at levels from lecturing to board memberships. The CSB PIs have supervised more than 50 PhD 
thesis projects. The results have been excellent; e.g. UH Medical Faculty thesis prize 1999, U of Oulu 
Medical Faculty thesis prize 2007, best population sciences thesis 2006, the UH thesis prize 2004 and 
2008. Several thesis works have been approved with distinction, by far exceeding the average <10% 
receiving this mark. The CSB PIs are represented in Boards of all the relevant Graduate Schools; Helsinki 
Biomedical Graduate School, Helsinki Graduate School in Biotechnology and Molecular Biology, and 
Finnish National Graduate School in Computational Biology. The PIs are also active in teaching genetics, 
bioinformatics and systems biology to MD and TRANSMED (MSc program in translation medicine) 
students. Thus the commitment of the CSB to the curricula of the Graduate Schools is firm and the link 
between the CSB and the Graduate Schools couldn’t be tighter.  
The PIs of CSB are also closely collaborating with Faculty of Science (Kumpula campus), and Institute 
Biotechnology (Viikki campus) in addition to obviously close relations to Faculty of Medicine and HUCH 
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in Meilahti. While our collaboration is focused on research, we also teach frequently in the other 
campuses and a large portion of our summer interns are from Kumpula or Viikki campuses. 
Good practices and quality assurance in doctoral training. 
Typically each student in CSB has two PI-level supervisors and PhD committee comprising 2-3 PI-level 
researchers. The committee gets together at least once in a year and the student explains his/her 
research and results. This assures that external but skilled panel of researchers comments periodically 
students’ progress. While students in the CSB have day-to-day hands-on guidance from post-docs, the 
students meet regularly with PIs and discuss plans, progress and results. This ensures that quality of the 
research remains high and possible issues can be solved early so that they do not grow to a crisis. As an 
indication of high quality and good practice in doctoral training is that the Aaltonen lab received the 
UH's Occupational Safety and Health Award 2005 as a formal acknowledgement of excellent working 
atmosphere. 
 
Assuring good career perspectives for the doctoral candidates/fresh doctorates. 
We strongly believe that the best possible prospect for a PhD or post-doc stem from excellent research 
results, experience in supervising students and contributing to grant applications. The most important 
from these is research as a typical career option for researchers graduating from CSB is academia or 
research and development in industry. We have been extremely successful in educating generations of 
researchers who have landed excellent post-doc and PI positions in academia as well as high R&D 
positions in industry in Finland and abroad. 
 RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions 
planned for their development. 
The major challenge for the holistic cancer research is getting talented students into research groups. 
Given multidisciplinary nature of our research, it is not enough to master one’s own field but also have 
at least some understanding on the basic concepts of the other, relevant fields. It is increasingly difficult 
to recruit students and post-docs who have strong skills in their own field and who are open to cross-
disciplinary research. Our actions have been to be active in both teaching in the curriculum cross-
disciplinary topics, as well as supervising students so that they experience cross-disciplinary research 
from the beginning of their career. However, we feel that it is important that the University clearly 
commits to support cross-disciplinary research and education not just in speeches but in practice with 
clear directed funding for these activities. Equally well we expect our proposal for an Academy of 
Finland’s Center of Excellence to be funded, to facilitate the further broadening of our approaches by 
adding computer sciences and epidemiology to the consortium. 
 
 
 Description of how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector).  
The societal impact of CSB relates mostly to expected advancements in management of cancer and 
cancer predisposition. We actively seek for opportunities to promote well-being in Finland and 
elsewhere, whether in form of breakthroughs of scientific, clinical, or commercial value. Of note, in 
particular prevention of cancer in predisposed individuals is an exceptionally valuable goal as the 
benefits focus on individuals on their most productive period of life, and already the results thus far 
achieved are world-leading with many lives saved. This greatly increases the impact of our research on 
health and wellbeing. It is also important to see that the data analysis platforms and approaches 
developed by the  CSB are not only valid for cancer research, but in many cases also for medical genetics 
in general. The CSB thus is an important player in ensuring that the proud traditions of this most 
3 SOCIETAL IMPACT OF RESEARCH AND DOCTORAL TRAINING (MAX. 4400 CHARACTERS WITH SPACES) 
 6 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 2 MATERIAL  
 
 
successful field of Finnish medical research are maintained, and the discipline continues to flourish on 
the highest international level. We have also been active in advising policy makers. Examples include 
active contributions in the preparations for the Academy law 2009 and Biobank legislation 2010, 
including several personal discussions with members of the parliament and Government Ministers. 
Aaltonen’s recent nominations as the Director of one of the Finnish Biocenters Biocentrum Helsinki, will 
position CSB well in the National network of policymaking in biosciences. Another prominent forum 
where CSB is represented by Aaltonen is the Advisory Board on Biotechnology (Biotekniikan 
neuvottelukunta). This  is a consultative body of experts in issues related to bio- and gene technology 
appointed by the Government for a term of three years. It aims to promote cooperation between 
authorities, researchers and operators in biotechnology and in particular gene technology, and it 
monitors developments and research in gene technology as well as its health and environmental 
impacts. In addition, it is the Board’s task to monitor and promote international cooperation in 
biotechnology and take into account the ethical considerations of gene technology.  
The dialog with laymen as well as professionals about the possibilities and risks in genetics is a field 
where CSB indeed has proud traditions, to be maintained. 
In this environment our doctoral student learn the ways to promote societal impact of research in their 
own work. High-quality researcher training on its own of course has significant societal impact, in 
accordance to the National strategies. Finland as a country of knowledge could not thrive without 
doctoral training programs aiming at – and reaching – levels of expertise comparable to the very best 
similar programs worldwide. 
 Ways to strengthen the societal impact of the RC’s research and doctoral training. 
Continuing excellence in field that has a major impact on public health is the key in strengthening the 
impact of our RC to society. We are already active in public forums (Vieraskynä column and interviews 
to the major newspaper Helsingin Sanomat, and other similar forums such as Aamulehti) as well as 
contributions to specialized magazines, such as Duodecim, which is subscribed by almost every Finnish 
medical doctor. For instance, SH has contributed to two articles to Duodecim on systems biology and 
computational analysis of cancer, as well as interviewed as the Colleague of the Week. Outreach, i.e., 
our efforts to contribute the discussion with “layman”, high-school students and specialists is an 
important aspect of research and promote both University of Helsinki in particular and excellent cross-
disciplinary research in general. We shall continue our efforts to support our students in their future 
careers, in Finland and elsewhere. As with other items in this review, one important way to step up CSB 




 Description of the RC’s research collaborations and joint doctoral training activities and how the RC 
has promoted researcher mobility.  
The RC's research collaborations and joint doctoral training activities. 
CSB as well as the research problem it is tackling are multidisciplinary at core, integrating medical 
genetics and molecular epidemiology (Aaltonen) with systems biology research in biomedicine (Taipale) 
and bioinformatics (Hautaniemi). All the PIs are from different backgrounds, are highly ambitious, 
energetic and at an active career stage; the passion for breakthrough science is strongly present. This, 
together with the interdisciplinary nature of the consortium results in formation of supportive, creative 
and inspirational research environment that enables both top-level research, and training of a new 
generation of scientists who will have the necessary skills to excel in their future careers and contribute 
4 INTERNATIONAL AND NATIONAL (INCL. INTERSECTORAL) RESEARCH COLLABORATION AND RESEARCHER 
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to the ongoing transformation of biomedicine from largely qualitative and descriptive approaches 
towards more exact, quantitative and predictive science. Regular meetings, at least twice per year on 
the whole CSB level, are seen as an important tool for evaluating past achievements and problems, 
exchanging ideas and experiences and planning for the future.  
An excellent and objective measure of networking nationally and internationally is the number and 
spectrum of coauthors in papers of the CSB PIs; please see the respective lists of publications.  
The members of this CSB have extensive national collaboration network. In bioinformatics and systems 
biology close collaboration with HIIT (Helsinki Institute for Information Technology; our collaborator 
Mäkinen as member), FIMM (Taipale, Aaltonen as associate members) and Biocenter Finland 
Bioinformatics Infrastructure Network (Hautaniemi as chairman) together with personal collaborations 
mean that all Finnish major groups who develop and apply computational methods to biomedical data 
are periodically met by the members of the CSB. This ensures that methods that are possibly provided 
by other groups in Finland and could be applicable in CSB can be deployed rapidly. Biocentrum Helsinki 
is an umberella organization supporting the networking of the best biotechnology groups in UH and 
Aalto University (currently 29 groups, all selected after peer review), and Aaltonen, Taipale, and 
Hautaniemi groups all are members of this key local organization, Aaltonen being the newly appointed 
Director of this organization. Clinical team members in CSB research and medical genetics units from all 
university hospitals are valuable collaborators for our nation-wide efforts. 
 
How the RC has promoted researcher mobility. 
Collaboration and mobility are ones of the strengths of CSB. We strongly encourage our PhD students to 
spend at least three months in a laboratory abroad. For instance, students from CSB have conducted 
research visits in MIT (USA), Nijgemen (Netherlands), KI (Sweden) and Oxford (UK), to mention a few. 
Furthermore, the PIs of this RC are mobile and frequent speakers in conferences and workshops. This 
brings forward novel collaboration possibilities with the other leading scientists. Indeed, this is seen as a 
number of EU, ERC and NIH projects we are committed and coordinating. 
 RC’s strengths and challenges related to research collaboration and researcher mobility, and the 
actions planned for their development. 
In studies on cancer genetics the proposed CSB is second to few or none in the world. It has thus been 
easy for us to establish the necessary international collaborations. In systems biology SH coordinates a 
FP7 ERANET SysBio consortium SYNERGY that contains partners from four EU countries, and JT a FP7 
project SYSCOL that has 11 partners from nine countries. In somatic colon cancer genetics CSB is in key 
position as part of the ICGC (official affiliation pending) effort to characterize colorectal cancer through 
genomic sequencing and other omics platforms. This consortium which was initiated by the CSB 
coordinator includes the top CRC research groups in the world, Ian Tomlinson (U of Oxford), Victor 
Velculescu and Bert Vogelstein (Johns Hopkins). In systems biology our major collaborators are Douglas 
Lauffenburger (MIT), Eran Segal (Weizmann) and Timothy Hughes (U. Toronto). We have not identified 




 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties).  
The description of research environment can be broken into two; Description of the National 
infrastructure relevant for the RC, and description of the local research environment. 
5 OPERATIONAL CONDITIONS (MAX. 4400 CHARACTERS WITH SPACES) 
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1) National infrastructure relevant for CSB 
The availability of unique national infrastructures and favorable attitudes and legislation form the basis 
of this research effort. Two key resources for the future are the Finnish Cancer Registry and the 
population registry center. Combination of cancer registry data and population registry data, as well as 
the genetic homogeneity of the population, provides powerful tools for detection of aberrant clustering 
of cancer cases. Use of resources such as systematic collections of paraffin embedded tissue specimens 
– particularly useful in cancer research – is enabled by legislation, as long as appropriate authorization 
has been granted. We have 16 years of experience in collaborating with Finnish pathology departments, 
and specimens can be found with great accuracy. The centralized national health care system enables 
also the efficient gathering of relevant patient record data from hospitals, when appropriately 
authorized. 
2) Local research environment 
The position of the Biomedicum campus as the most impressive cluster of biomedical research 
infrastructure in the country is well established. As depicted above the unique materials can be 
efficiently utilized based on advanced but well-working genome-wide tools such as high throughput 
sequencing, SNP microarrays on normal as well as tumor DNA, CGH array on normal and tumor DNA, as 
well as transcriptome analyses on normal and tumor RNA (being replaced by RNA-sequencing). All these 
platforms are at routine use within CSB and the required technology is conveniently available through 
the local core facilities Biomedicum Genomics and FIMM Technology Center. Several other campus core 
facilities such as Virus Core Facility, Molecular Imaging Unit, Biomedicum High Throughput Center, and 
Biomedicum Experimental Animal Center may also be utilized providing excellent assistance in carrying 
out sophisticated functional experiments. The Research and Innovation Services of the University of 
Helsinki gives high quality support services for the CSB researchers from project planning to proposal 
preparation, contract negotiation, implementation and exploitation of the results. All the CSB laboratory 
and office space are located next to each other at the Biomedicum 5th floor enabling easy 
communication between the groups at all levels.  
RC efforts are strongly supported by the University of Helsinki / Medical Faculty as well as the Academy 
of Finland. All CSB PIs are members of the Faculty's 5-year research program "Genome-Scale Biology" 
(2007-2011, the coordinator as the current director) and two PIs belong to the Academy of Finland’s 
Center of Excellence in Translational Genome-Scale Biology (2006-2011). 
Research and teaching duties 
The main focus of the CSB is on highest level research. Teaching focuses on pre- and postgraduate 
students within the groups, with the aim of providing them the best possible supervision both at the 
strategic as well as day-to-day hands-on level. Naturally, the senior members of the team are involved in 
various training activities on the campus and elsewhere. 
 RC’s strengths and challenges related to operational conditions, and the actions planned for their 
development. 
The biggest strength of the CSB is the well-established collaboration between the three world-leading 
groups who all have their well-defined roles and expertise that complement each other. The close 
collaboration will likely continue in the framework of Academy’s CoE as well as through Faculty’s 
research program. Physical location next to each other at the leading biomedical research institute in 
Finland provides excellent means to easily organize collaborative efforts, to utilize cutting edge 
technologies, and to continue pursuing scientific research at the highest level. A major challenge related 
to operational conditions is the continuous need to upgrade the supporting research infrastructure. 
Without expensive state-of-the-art technologies CSB research cannot be competitive, and the 
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commitment of the University to our field of research is not only welcome but essential for future 




 Description of the execution and processes of leadership in the RC, how the management-related 
responsibilities and roles are distributed in the RC and how the leadership- and management-related 
processes support high quality research, collaboration between principal investigators and other 
researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.  
CSB is a research community formed by three independent research groups and as such does not have a 
particular management structure. Efforts towards scientific breakthroughs dictate the actions, rather 
than decisions of a governing body or director. All groups are members of Genome-Scale Biology 
Research Program, where Aaltonen happens to be the director. Similarly, the Center of Excellence 
proposal which is the key for future actions is coordinated by Aaltonen. Thus it seemed conceivable that 
Aaltonen also acts as the contact person of the Research Community, but this could have equally well 
been any other PI. Our mode of administration is network management. The CSB is a focused and simple 
Research Community with a flat organizational profile; 3 teams with clear roles and strengths, working 
together.  
Within the groups the structure needs to be more organized. Senior scientists have significant roles e.g. 
in supervising PhD students, organizing day-to-day work in the laboratories and participating in writing 
the grant applications and reports. This enables efficient advancement of the projects and at the same 
time is extremely useful for the senior scientists themselves as they gain valuable experience in 
administrative, tutorial and organizational matters which come most valuable when starting their own 
and independent research groups. 
Collaboration between the three CSB research groups is close at all possible levels. The PIs vision the 
future strategies and discuss their implementation and study design with senior scientists, who with 
doctoral students organize and execute them in practice. Also the laboratory personnel frequently asks 
tips and guidance from other CSB groups who already have experience in specific practical issues. One 
major advantage is naturally the physical location of all CSB groups next to each other. As people from 
the three groups see each other at the basically daily basis, they have gotten to know each other rather 
well, making it very easy to approach members from other groups and also organize meetings often and 
on a short notice or spontaneously. Relaxed atmosphere and informal relationships between and within 
the groups also allows and encourages students to express their ideas and suggestions for open 
discussion; indeed this is what one calls a “creative research environment”.  
As all three groups are world-leaders in their own field, they naturally have other collaborations also 
outside the context of CSB. New insights and innovative ideas from these collaborations, naturally 
within the limit that confidentiality provides, is distributed between the CSB and within the individual 
research groups. Also students of this RC are encouraged to actively discuss and present their on-going 
work to fellow students in the other two labs. 
 RC’s strengths and challenges related to leadership and management, and the actions planned for 
developing the processes. 
An obvious strength is that all actions arise from needs of scientific excellence, and this will not change 
in the future. In management the RC aims to adopt useful tools such as yearly risk analysis, already in 
use in the coordinators group with excellent results. This analysis covers issues ranging from ergonomics 
6 LEADERSHIP AND MANAGEMENT IN THE RESEARCHER COMMUNITY (MAX. 4400 CHARACTERS WITH SPACES) 
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to other aspects of well-being at work, such as stress related issues. Monitoring these allow efficient and 
early interventions and help in maintaining a pleasant, relaxed, and creative working atmosphere. 
A clear challenge is the growing administrative workload of the PIs. To cope with this many tasks have 
been delegated to the other senior scientists to ensure fluent advancement of the projects. There is a 
risk that new paperwork related duties are implemented whenever useful from the administrative point 
of view, with little interest to monitor the cumulative impact of these measures to creative scientific 





 Listing of the RCs external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 
 Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC 
members during 1.1.2005-31.12.2010: 4490000 
 
 Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) 
TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010: 0 
 
 European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members 
during 1.1.2005-31.12.2010: 2910000 
 
 European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the 
RC members during 1.1.2005-31.12.2010: 4680000 
 
 International and national foundations – names of international and national foundations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros).  
- names of the foundations: Sigrid Juselius, AICR, Finnish Cancer Organizations 
- total amount of funding (in euros) from the above-mentioned foundations: 2210000 
 
 Other international funding - names of other international funding organizations which have decided to 
allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in 
euros). 
- names of the funding organizations:  
- total amount of funding (in euros) from the above-mentioned funding organizations: 0 
 
 Other national funding (incl. EVO funding and Ministry of Education and Culture funded doctoral 
programme positions) - names of other national funding organizations which have decided to allocate 
funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros). 
- names of the funding organizations: EVO, Ministry of Education, U of Helsinki, Biocentrum 
Helsinki, VTT, CIMO, FIMM 
- total amount of funding (in euros) from the above-mentioned funding organizations: 2910000 
 
7 EXTERNAL COMPETITIVE FUNDING OF THE RC 
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 Description of the RC’s future perspectives in respect to research and doctoral training. 
As indicated above, key discoveries are anticipated in the following fields of research relevant for CSB 
Research Community: 
i) Identification of high/moderate-penetrance cancer predisposition conditions, and the respective 
susceptibility genes. 
ii) Characterization of common cancer susceptibility variants. In particular, little is known about the 
biology underlying these variants – starting from identification of the causative variants from the 
associated genomic regions. 
iii) Characterization of mutatomes of all clinically relevant tumor types. 
To discover high/moderate penetrance loci (i) our main tool will be the Finnish Cancer Registry (FCR). 
The combined use of the National Population Registries (NPR) and FCR will enable systematic detection 
of clusters of specific types of cancer based on geographical clustering and clustering by family name at 
birth. This resource of 1 000 000 cancer probands will provide us with a significant advantage as 
compared with competitors, in recruiting key patients, as well as in subsequent stages in validation such 
as detailed characterization of new susceptibility phenotypes. For colorectal cancer (CRC) we are in good 
position with already existing materials and we shall create whole genome data from our familial CRC 
patient materials, to discover predisposition changes in particular in genomic regions predicted to 
function in gene regulation. 
For characterization of common cancer susceptibility variants (ii) we will focus on CRC, where our key 
collaborator in view of GWAS data is EU COGENT consortium. COGENT has created data on 50 000 CRC 
cases and 50 000 cancer free controls to identify the key loci predisposing to common CRC. Such data is 
often descriptive, and much work needs to be done before the causative changes are identified and 
mechanisms of disease unraveled. The associated regions will be scrutinized in CSB through our 
innovative in-silico and experimental approaches as exemplified in our recent article (Tuupanen et al, 
Nature Genetics 2009). 
The CSB will contribute to systematic analysis of tumor mutatomes (iii) focusing on CRC and uterine 
leiomyomas. The number of well documented CRC/normal tissue fresh sample pairs in our unit exceeds 
1500. 200 fresh frozen uterine leiomyoma/normal myometrium pairs are available. These efforts will 
result in a comprehensive catalogue of somatic mutations in a large number of tumors. 
CSB scrutinizes patient samples by genome-wide approaches, such as genomic sequencing, RNA-seq, 
and copy number variation arrays. Advanced computer science methods are used to translate the raw 
data from these approaches into knowledge. In addition, sophisticated system biology approaches will 
be developed and utilized to model the effects of the identified variants: e.g. computational methods, 
functional approaches, and high-throughput screening methods. 
A new CoE proposal (now shortlisted for final decision) which involves all the three RC groups is a key for 
the future research actions. 
CSB aims to continue providing doctoral training on the highest national and international level. The 
good practices implemented will be carefully maintained and developed. 
The major advance would be the promotion of student exchange both within the CSB groups and on an 
international level. For students with a biological/medical background, this could include getting familiar 
with computational tools and respectively for bioinformatics/computing students the possibility to work 
8 RC’S STRATEGIC ACTION PLAN FOR 2011–2013 (MAX. 4400 CHARACTERS WITH SPACES) 
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in a wetlab environment. The CSB network would improve the standard of international visits through 
the formation of a broader contact network through the group leaders. PhD research training could also 
be improved by systematically offering students not enrolled in Graduate Schools the possibility for 
comparable benefits, such as a thesis committee. Regular research discussions or journal clubs creating 
a relaxed setting where students could practice and improve their scientific thinking are also desired. 
The CSB network could promote personal development, which is rarely targeted in the currently 
available programs. The CSB could organize courses related to leadership, networking and presentation 
skills. A CSB alumni-network could be formed where alumni members of the groups presented their 




The CSB group leaders Aaltonen, Hautaniemi & Taipale first drafted the document in several successive 
rounds. Subsequently the document was further expanded and polished by postdoctoral members of 
the RC, in particular Docents Auli Karhu and Pia Vahteristo. The views of the predoctoral students were 
collected by Anna-Maria Lahesmaa-Korpinen, and all predocs of the RC had the opportunity – and were 
encouraged to - express their views, and many of them indeed did. Technical assistance was provided by 
Sirpa Soisalo, Tiia Pelkonen, and Ritva Lautala. 
9 SHORT DESCRIPTION OF HOW THE RC MEMBERS HAVE CONTRIBUTED TO THE COMPILATION OF THE STAGE 2 
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1 Analysis of publications 
 
- Associated person is one of Lauri Antti Aaltonen ,  Mervi Aavikko ,  Pia Pauliina Alhopuro , 
 Alexandra Gylfe , Elina Heliövaara ,  Eevi Kaasinen ,  Auli 
Inkeri Karhu ,  Johanna Kondelin ,  ,  Virpi Launonen ,  Heli 
Lehtonen ,  Miika Mehine ,  Iina Niittymäki ,  Silva Saarinen ,  
Sari Tuupanen , Pia Marita Vahteristo ,  Sampsa Hautaniemi ,  Ping Chen , 
 Sirkku Helena Karinen ,  Marko Kalevi Laakso ,  Anna-Maria Kristiina Lahesmaa-Korpinen , 
Riku Louhimo ,  Kristian Ovaska , Ville Rantanen , 
Vladimir Rogojin ,  Jianmin Wu ,  Jussi Taipale , Albertus Wilhelm Martinus Bonke , 
 Outi Hallikas ,  ,  Arttu Jolma ,  Songping Li ,  
Maria Sokolova ,  Mikko Turunen ,  Anna Valpuri Vähärautio , Gonghong Wei , 
 Jian Yan 
 
                   Publication year 
Publication type 2005 2006 2007 2008 2009 2010 
Total Count 2005 - 
2010 
A1 Refereed journal article 24 25 26 21 21 25 142 
A2 Review in scientific journal  1 2 2  1 6 
A3 Contribution to book/other compilations (refereed)   1  1  2 
B1 Unrefereed journal article  4     4 
B3 Unrefereed article in conference proceedings      1 1 
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Aaltonen, LA, Romeo, G, Karhu, A 2009, 'Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial 
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Rajecki, M, af Hällström, T, Hakkarainen, T, Nokisalmi, P, Hautaniemi, S, Nieminen, AI, Tenhunen, M, Rantanen, V, Desmond, RA, 
Chen, D, Guse, K, Stenman, U, Gargini, R, Kapanen, M, Klefström, J, Kanerva, A, Pesonen, S, Ahtiainen, L, Hemminki, A 2009, 'Mre11 
inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation', International Journal of 
Cancer, vol 125, no. 10, pp. 2441-2449. 
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Wu, J, Vallenius, T, Ovaska, K, Westermarck, J, Makela, TP, Hautaniemi, S 2009, 'Integrated network analysis platform for protein-
protein interactions', Nature methods., vol 6, no. 1, pp. 75-77. 
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Dias, JD, Liikanen, I, Guse, K, Foloppe, J, Sloniecka, M, Diaconu, I, Rantanen, V, Eriksson, KM, Hakkarainen, T, Lusky, M, Erbs, P, 
Escutenaire, S, Kanerva, A, Pesonen, S, Cerullo, V, Hemminki, A 2010, 'Targeted Chemotherapy for Head and Neck Cancer with a 
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for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33', Nature Genetics, vol 42, no. 11, pp. 973-U89. 
Jolma, A, Kivioja, T, Toivonen, J, Cheng, L, Wei, G, Enge, M, Taipale, M, Vaquerizas, JM, Yan, J, Sillanpää, MJ, Bonke, AWM, Palin, K, 
Talukder, S, Hughes, TR, Luscombe, NM, Ukkonen, E, Taipale, J 2010, 'Multiplexed massively parallel SELEX for characterization of 
human transcription factor binding specificities',  Genome Research, vol 20, no. 6, pp. 861-873. 
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Kaasinen, E, Aittomaki, K, Eronen, M, Vahteristo, P, Karhu, A, Mecklin, J, Kajantie, E, Aaltonen, LA, Lehtonen, R 2010, 'Recessively 
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Hautaniemi, S, Vallenius, T, Mäkelä, T 2006, 'Systeemibiologia syöpätutkimuksessa: [katsaus]', Duodecim, vol 122, pp. 2484-2490. 
2007 
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2010 
Laakso, MK, Karinen, SH, Lehtonen, RJ, Hautaniemi, S 2010, 'Computational Identification of Cancer Susceptibility Loci', Methods in 
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A3 Contribution to book/other compilations (refereed) 
2007 
Aaltonen, LA, Järvinen, HJ 2007, 'Paksusuolisyövälle altistavat geenivirheet ja niiden diagnostiikka', Gastroenterologia ja hepatologia, 
Duodecim, Helsinki, pp. 544-549. 
2009 
Monni, O, Hautaniemi, S 2009, 'Bioinformatics of gene expression and copy number data integration',  Statistics and Informatics in 
Molecular Cancer Research, Oxford Scholarship Online Monographs, pp. 78-102. 
B1 Unrefereed journal article 
2006 
Aaltonen, LA 2006, 'Periytyvän kasvainalttiuden molekyylitausta: Äyräpään luento',  Duodecim, vol 122, no. 18, pp. 2221-2230. 
Arango, D, Alhopuro, P, Aaltonen, LA 2006, 'In response: SMAD4 levels and allelic imbalance in 18q21 in colorectal cancer',  Clinical 
Cancer Research, vol 12, no. 5, pp. 1654-1655. 
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Vierimaa, O, Georgitsi, M, Lehtonen, R, Vahteristo, P, Kokko, A, Raitila, A, Tuppurainen, K, Ebeling, T, Salmela, PI, Paschke, R, 
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adenomalle: [referaatti Science lehden artikkelista]', Duodecim, vol 122, no. 12, pp. 1419-1420. 
B3 Unrefereed article in conference proceedings 
2010 
Laiho, M, Jäämaa, SS, af Hällström, TM, Sankila, A, Rantanen, V, Zhang, Z, Yang, Z, De Marzo, AM, Ruutu, M, Andersson, LC  2010, 
DNA Damage Recognition via Activated ATM Pathway in Non-proliferating Human Prostate Tissue: Proceedings of the 52nd Annual 
ASTRO Meeting,, International Journal of Radiation: Oncology - Biology - Physics 78 3; suppl. 1 ELSEVIER INC.. 
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1 Analysis of activities 2005-2010 
 
- Associated person is one of Lauri Antti Aaltonen ,  Mervi Aavikko ,  Pia Pauliina Alhopuro , 
 Alexandra Gylfe , Elina Heliövaara ,  Eevi Kaasinen ,  Auli 
Inkeri Karhu ,  Johanna Kondelin ,  ,  Virpi Launonen ,  Heli 
Lehtonen ,  Miika Mehine ,  Iina Niittymäki ,  Silva Saarinen ,  
Sari Tuupanen , Pia Marita Vahteristo ,  Sampsa Hautaniemi ,  Ping Chen , 
 Sirkku Helena Karinen ,  Marko Kalevi Laakso ,  Anna-Maria Kristiina Lahesmaa-Korpinen , 
Riku Louhimo ,  Kristian Ovaska , Ville Rantanen , 
Vladimir Rogojin ,  Jianmin Wu ,  Jussi Taipale , Albertus Wilhelm Martinus Bonke , 
 Outi Hallikas ,  ,  Arttu Jolma ,  Songping Li ,  
Maria Sokolova ,  Mikko Turunen ,  Anna Valpuri Vähärautio , Gonghong Wei , 
 Jian Yan 
 
 
     
Activity type 
Supervisor or co-supervisor of doctoral thesis 51 
Prizes and awards 17 
Editor of research journal 4 
Peer review of manuscripts 72 
Assessment of candidates for academic posts 5 
Membership or other role in review committee 2 
Membership or other role in research network 6 
Membership or other role in national/international committee, council, board 13 
Membership or other role in public Finnish or international organization 10 
Participation in interview for written media 5 
Participation in TV programme 1 
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2 Listing of activities 2005-2010 
Supervisor or co-supervisor of doctoral thesis 
Lauri Antti Aaltonen ,  
Doctoral Thesis supervision / Lehtonen R, Lauri Antti Aaltonen, 1999  2006, Finland 
Doctoral Thesis supervision / Ylisaukko-oja, Lauri Antti Aaltonen, 1999  2007, Finland 
Doctoral Thesis supervision / Hienonen, Lauri Antti Aaltonen, 2000  2005, Finland 
Doctoral Thesis supervision / Laiho, Lauri Antti Aaltonen, 2000  2005, Finland 
Doctoral Thesis supervision / Vanharanta, Lauri Antti Aaltonen, 2002  2006, Finland 
Doctoral Thesis supervision / Alhopuro, Lauri Antti Aaltonen, 2003  2007, Finland 
Doctoral Thesis supervision / Kokko, Lauri Antti Aaltonen, 2003  2006, Finland 
Doctoral Thesis supervision / Lehtonen H, Lauri Antti Aaltonen, 2003  2008, Finland 
Doctoral Thesis supervision / Sammalkorpi, Lauri Antti Aaltonen, 2003  2008, Finland 
Doctoral Thesis supervision / Vierimaa, Lauri Antti Aaltonen, 2004  2008, Finland 
Doctoral Thesis Supervision / Saarinen, Lauri Antti Aaltonen, 2005  …, Finland 
Doctoral Thesis supervision / Ahvenainen, Lauri Antti Aaltonen, 2005  2010, Finland 
Doctoral Thesis supervision / Georgitsi, Lauri Antti Aaltonen, 2005  2008, Finland 
Doctoral Thesis supervision / Koski, Lauri Antti Aaltonen, 2005  18.06.2010 
Doctoral Thesis supervision / Tuupanen, Lauri Antti Aaltonen, 2005  2009, Finland 
Doctoral Thesis supervision / Raitila, Lauri Antti Aaltonen, 2006  2009, Finland 
Doctoral Thesis supervision / Heliövaara, Lauri Antti Aaltonen, 2007  …, Finland 
Doctoral Thesis supervision / Gylfe, Lauri Antti Aaltonen, 2008  …, Finland 
Doctoral Thesis supervision / Aavikko, Lauri Antti Aaltonen, 2009  …, Finland 
Doctoral Thesis supervision / Kaasinen, Lauri Antti Aaltonen, 2009  …, Finland 
Doctoral Thesis supervision / Sirkiä, Lauri Antti Aaltonen, 2010  …, Finland 
Auli Inkeri Karhu ,  
Supervision of doctoral thesis, Auli Inkeri Karhu, 2001  2005, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 08.10.2001  08.10.2005, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 2003  2007, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 2003  2008, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 08.10.2003  08.06.2007, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 08.10.2003  02.11.2008, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 2005  2008, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 2005  2009, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 08.10.2005  12.06.2009, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 08.10.2005  24.10.2008, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 2006  2009, Finland 
Supervision of doctoral thesis, Auli Inkeri Karhu, 08.10.2006  21.12.2009, Finland 
Virpi Launonen ,  
Doctoral thesis supervision / Ylisaukko-oja, Virpi Launonen, 1999  2007, Finland 
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Doctoral thesis supervision / Lehtonen H., Virpi Launonen, 2003  2008, Finland 
Doctoral thesis supervision / Ahvenainen, Virpi Launonen, 2005  2010, Finland 
Doctoral thesis supervision / Lehtonen R., Virpi Launonen, 2006, Finland 
Sampsa Hautaniemi ,  
Doctoral thesis supervision / Valiathan, Sampsa Hautaniemi, 2006, United States 
Doctoral thesis supervision / Laakso, Sampsa Hautaniemi, 2007  … 
Doctoral thesis supervision / Lahesmaa-Korpinen, Sampsa Hautaniemi, 2007  … 
Doctoral thesis supervision / Autio, Sampsa Hautaniemi, 24.09.2008, Finland 
Doctoral thesis supervision / Karinen, Sampsa Hautaniemi, 2008  … 
Doctoral thesis supervision / Chen, Sampsa Hautaniemi, 2009  … 
Doctoral thesis supervision / Ovaska, Sampsa Hautaniemi, 2009  … 
Doctoral thesis supervision / Rantanen, Sampsa Hautaniemi, 2009  … 
Jussi Taipale ,  
Doctoral Thesis supervision / Turunen, Jussi Taipale, 01.11.2006  …, Finland 
Doctoral Thesis supervision / Jolma, Jussi Taipale, 01.2007  …, Finland 
Doctoral Thesis supervision / Varjosalo, Jussi Taipale, 2008, Finland 
Doctoral Thesis supervision / Yan, Jussi Taipale, 2008  …, Finland 
Doctoral Thesis supervision / Hallikas, Jussi Taipale, 2009, Finland 
Prizes and awards 
Lauri Antti Aaltonen ,  
Academy Professor, Lauri Antti Aaltonen, 08.2002  07.2007, Finland 
Nominee for Descartes Prize, Lauri Antti Aaltonen, 2005 
University of Helsinki's Occupational safety and health award, Lauri Antti Aaltonen, 2005, Finland 
Matti Äyräpää Prize, Lauri Antti Aaltonen, 2006, Finland 
Professor of Tumor Genomics, Lauri Antti Aaltonen, 08.2007  …, Finland 
Academy Professor, Lauri Antti Aaltonen, 2009  …, Finland 
ERC Advanced Grant, Lauri Antti Aaltonen, 2010 
Sampsa Hautaniemi ,  
The Finnish Medical Foundation 50-years jubileum award, Sampsa Hautaniemi, 2010 
Marko Kalevi Laakso ,  
MBI Master's thesis award, Marko Kalevi Laakso, 01.01.2007, Finland 
Jussi Taipale ,  
Sigrid Juselius Young Investigator Award, Jussi Taipale, 2005, Finland 
EMBO Young Investigator, Jussi Taipale, 2006 
Medix Prize, Jussi Taipale, 2006 
Academy Professor, Jussi Taipale, 2008  2012 
Anders Jahre Young Researcher award, Jussi Taipale, 2008 
ERC Advanced Grant, Jussi Taipale, 2009 
Professor of Medical Systems Biology, Jussi Taipale, 2009  …, Sweden 
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Editor of research journal 
Lauri Antti Aaltonen ,  
Journal of Medical Genetics, Lauri Antti Aaltonen, 1999  2005, United Kingdom 
International Journal of Cancer, Lauri Antti Aaltonen, 2003  2005, United States 
Acta Oncologica, Lauri Antti Aaltonen, 2004  2008, United Kingdom 
Cancer Genomics &amp; Proteomics, Lauri Antti Aaltonen, 2004  …, Greece 
Peer review of manuscripts 
Lauri Antti Aaltonen ,  
British Journal of Cancer, Lauri Antti Aaltonen, 2005  2010 
Cancer Research, Lauri Antti Aaltonen, 2005  2009 
Chromosomes &amp; Cancer, Lauri Antti Aaltonen, 01.01.2005  31.12.2005 
Clinical Gastroenterology and Hepatology, Lauri Antti Aaltonen, 2005 
Gastroenterology, Lauri Antti Aaltonen, 2005  2009 
Genes, Lauri Antti Aaltonen, 01.01.2005  31.12.2005 
Genes, Chromosomes &amp; Cancer, Lauri Antti Aaltonen, 2005  2009 
Human Molecular Genetics, Lauri Antti Aaltonen, 01.01.2005  31.12.2006 
International Journal of Cancer, Lauri Antti Aaltonen, 2005  2011 
Journal of Clinical Investigation, Lauri Antti Aaltonen, 01.01.2005  31.12.2005 
Journal of Medical Genetics, Lauri Antti Aaltonen, 2005  2010 
Journal of Molecular Diagnostics, Lauri Antti Aaltonen, 01.01.2005  31.12.2005 
Journal of the national Cancer Institute, Lauri Antti Aaltonen, 01.01.2005  31.12.2005 
Oncogene, Lauri Antti Aaltonen, 2005  2020 
Science, Lauri Antti Aaltonen, 01.01.2005  31.12.2005 
Acta-Dermato Venereologica, Lauri Antti Aaltonen, 2006 
Acta-Oncologica, Lauri Antti Aaltonen, 2006 
British Journal of Dermatology, Lauri Antti Aaltonen, 2006 
Clinical Cancer Research, Lauri Antti Aaltonen, 2006  2010 
Human Mutation, Lauri Antti Aaltonen, 2006  2009 
Journal of Clinical Endocrinology and Metabolism, Lauri Antti Aaltonen, 2006  2008 
Molecular and Cellular Oncology, Lauri Antti Aaltonen, 03.2006  05.2006 
Nature Clinical Practise Oncology, Lauri Antti Aaltonen, 2006 
Proceedings of the National Academy of Sciences, Lauri Antti Aaltonen, 2006  2010 
Trends in Molecular Medicine, Lauri Antti Aaltonen, 2006 
Cancer Detection and Prevention, Lauri Antti Aaltonen, 2007 
Journal of Pathology, Lauri Antti Aaltonen, 2007 
Lancet Oncology, Lauri Antti Aaltonen, 2007 
Nature, Lauri Antti Aaltonen, 2007  2010 
New England Journal of Medicine, Lauri Antti Aaltonen, 2007  2010 
Molecular Genetics and Metabolism, Lauri Antti Aaltonen, 2008 
EMBO Journal, Lauri Antti Aaltonen, 2009 
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Familial Cancer, Lauri Antti Aaltonen, 2009  2010 
Hormone Research, Lauri Antti Aaltonen, 2009 
Journal of the American Medical Association, Lauri Antti Aaltonen, 2009 
Lancet, Lauri Antti Aaltonen, 2009 
Nature Genetics, Lauri Antti Aaltonen, 2009  2010 
PLoS Biology, Lauri Antti Aaltonen, 2009  2010 
Clinical Genetics, Lauri Antti Aaltonen, 01.01.2010  31.12.2010 
Auli Inkeri Karhu ,  
Expert Review of Endocrinology &amp; Metabolism, Auli Inkeri Karhu, 08.10.2008 
European Journal of Endocrinology, Auli Inkeri Karhu, 08.10.2009 
International Journal of Cancer, Auli Inkeri Karhu, 08.10.2010 
Virpi Launonen ,  
British Journal of Cancer, Virpi Launonen, 01.01.2004  31.12.2006, United Kingdom 
Oncogene, Virpi Launonen, 19.09.2005  31.12.2005 
Genetic Disease Online Reviews, Virpi Launonen, 12.04.2006  31.12.2006, United States 
Journal of Dermatological Science, Virpi Launonen, 04.09.2006  31.12.2006, Japan 
Nature Clinical Practice Urology, Virpi Launonen, 17.10.2006  31.12.2006, United States 
Sampsa Hautaniemi ,  
BMC Bioinformatics, Sampsa Hautaniemi, 2003  … 
BMC Genomics, Sampsa Hautaniemi, 2003  … 
BioTechniques, Sampsa Hautaniemi, 2003  … 
Bioinformatics, Sampsa Hautaniemi, 2003  … 
Clinical Chemistry, Sampsa Hautaniemi, 2005  … 
Data Mining and Knowledge Discovery, Sampsa Hautaniemi, 2005  … 
FEBS Letters, Sampsa Hautaniemi, 2005  … 
IEEE Transactions on Signal Processing, Sampsa Hautaniemi, 2005  … 
Neurocomputing, Sampsa Hautaniemi, 2005  … 
Jussi Taipale ,  
Development, Jussi Taipale, 2005 
Molecular Cancer Research, Jussi Taipale, 2005  2006 
Current Biology, Jussi Taipale, 2006 
Developmental Cell, Jussi Taipale, 2006  2010 
Cell Stem Cell, Jussi Taipale, 2007 
Nature Cell Biology, Jussi Taipale, 2007 
Nature Methods, Jussi Taipale, 2007  2010 
Cancer Cell, Jussi Taipale, 2008 
Nature, Jussi Taipale, 2008 
PLOS Biology, Jussi Taipale, 2008 
Genes &amp; Development, Jussi Taipale, 2009  2010 
Molecular Systems Biology, Jussi Taipale, 2009 
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Genome Research, Jussi Taipale, 2010 
Proceedings of the National Academy of Sciences, Jussi Taipale, 2010 
Assessment of candidates for academic posts 
Lauri Antti Aaltonen ,  
Examiner for Professorship, Lauri Antti Aaltonen, 2005, United States 
Examiner for Docentship / Mottagui-Tabarin, Lauri Antti Aaltonen, 2006, Finland 
Examiner for Professorship / Sorsa, Lauri Antti Aaltonen, 2009, Finland 
Jussi Taipale ,  
Reviewer for Docentship, Jussi Taipale, 2007, Finland 
Reviewer for Professorship, Jussi Taipale, 2009, Canada 
Membership or other role in review committee 
Lauri Antti Aaltonen ,  
Member of the Finnish Cancer Society's Grant Review Board, Lauri Antti Aaltonen, 2004  2007, Finland 
Sampsa Hautaniemi ,  
Member of the scientific evaluation board for HPC-Europa2, Sampsa Hautaniemi, 2009  … 
Membership or other role in research network 
Lauri Antti Aaltonen ,  
Membership in the Nordic Center of Excellence in Disease Genetics, Lauri Antti Aaltonen, 2000  …, Finland 
Membership in the Center of Excellence in Translational Genome-Scale Biology, Lauri Antti Aaltonen, 2006  2011, Finland 
Sampsa Hautaniemi ,  
Board membership in Quantitative biology infrastructure network, Sampsa Hautaniemi, 2007  2008, Finland 
Chairman of the Bioinformatics infrastucture network, Sampsa Hautaniemi, 2009  2012, Finland 
Jussi Taipale ,  
Membership in the Nordic Center of Excellence in Disease Genetics, Jussi Taipale, 2005  … 
Membership in the Center of Excellence in Translational Genome-Scale Biology, Jussi Taipale, 2006  2011, Finland 
Membership or other role in national/international committee, council, board 
Lauri Antti Aaltonen ,  
Membership in the EACR Committee for Central and Eastern Europe, Lauri Antti Aaltonen, 1999  … 
Membership in the Danish Cancer Society's Scientific and Medical Advisory Board, Lauri Antti Aaltonen, 2003  2006, Denmark 
Membership in the EMBO Science &amp; Society Committee, Lauri Antti Aaltonen, 2003  2006 
Academy of Finland, Lauri Antti Aaltonen, 01.01.2005  31.12.2005, Finland 
Board membership in Viikki Doctoral Programme in Molecular Biosciences, Lauri Antti Aaltonen, 01.01.2005  31.12.2005, Finland 
Finnish Cancer Organisations, Lauri Antti Aaltonen, 01.01.2005  31.12.2005, Finland 
Board membership in Helsinki Biomedical Graduate School (HBGS), Lauri Antti Aaltonen, 2008  …, Finland 
Sampsa Hautaniemi ,  
Board membership in Bioinformatics Communities Committee at ESFRI project ELIXIR, Sampsa Hautaniemi, 2008  … 
Deputy membership in the Institute of Biotechnology steering board, Sampsa Hautaniemi, 2010  2014, Finland 
Jussi Taipale ,  
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Board membership in Graduate School in Computational Biology, Bioinformatics and Biometry (ComBi), Jussi Taipale, 2008  …, 
Finland 
Board membership in Helsinki Graduate School in Biotechnology and Molecular Biology (GSBM), Jussi Taipale, 2008  2009, Finland 
Board membership in Finnish Graduate School in Computational Sciences (FICS), Jussi Taipale, 01.01.2010  …, Finland 
Membership or other role in public Finnish or international organization 
Lauri Antti Aaltonen ,  
Membership in Duodecim, Lauri Antti Aaltonen, 1986  …, Finland 
Membership in the Europan Association for Cancer Research, Lauri Antti Aaltonen, 1997  … 
Membership in the European Molecular Biology Organization (EMBO), Lauri Antti Aaltonen, 2000  … 
Membership in Biocentrum Helsinki, Lauri Antti Aaltonen, 2001  …, Finland 
Membership in the Finnish Academy of Science and Letters, Lauri Antti Aaltonen, 2002  …, Finland 
Director of Genome Scale Biology Research Program, Lauri Antti Aaltonen, 2009  …, Finland 
Membership in the European Academy of Cancer Sciences, Lauri Antti Aaltonen, 2010  … 
Sampsa Hautaniemi ,  
Deputy member of the Faculty of Medicine Senate, Sampsa Hautaniemi, 2009  2012, Finland 
Vice director (infrastructures and research training) of the Research Programs Unit, Sampsa Hautaniemi, 2010  2012, Finland 
Jussi Taipale ,  
Membership in Biocentrum Helsinki, Jussi Taipale, 2007  …, Finland 
Participation in interview for written media 
Lauri Antti Aaltonen ,  
Interviews in newspaper / Helsingin Sanomat, Lauri Antti Aaltonen, 06.01.2005  …, Finland 
Sampsa Hautaniemi ,  
Magazine and journal interviews, Sampsa Hautaniemi, 2007  … 
Interviews for newspaper / Helsingin Sanomat, Sampsa Hautaniemi, 2008  …, Finland 
Jussi Taipale ,  
Interview in a newspaper / Helsingin Sanomat, Jussi Taipale, 23.02.2006, Finland 
Interview in the Journal of Cell Biology, Jussi Taipale, 28.07.2008 
Participation in TV programme 
Lauri Antti Aaltonen ,  
Interview in YleTeema, Lauri Antti Aaltonen, 30.11.2005, Finland 
Participation in interview for web based media 
Lauri Antti Aaltonen ,  
Participation in Radio Helsinki podcast, Lauri Antti Aaltonen, 14.11.2005, Finland 
Sampsa Hautaniemi ,  
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Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010  
by CWTS, Leiden University, the Netherlands 
Research Group: Aaltonen L 
Basic statistics 
Number of publications (P) 143 
Number of citations (TCS) 2,649 
Number of citations per publication (MCS)  18.72 
Percentage of uncited publications 18% 
Field-normalized number of citations per publication (MNCS)   1.83 
Field-normalized average journal impact (MNJS)   2.00 
Field-normalized proportion highly cited publications (top 10%)   2.42 
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